Repligen | RGEN - Gross Profit On Sales


Repligen reported $108.28M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Agilent USD 990M 44M Mar/2026
Align Technology USD 736.59M 53M Mar/2026
Bio Techne USD 208.29M 17.01M Mar/2026
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Bristol-Myers Squibb USD 8.41B 381M Dec/2025
Bruker USD 379.8M 69.4M Mar/2026
Charles River Laboratories USD 279.32M 7.36M Mar/2026
Danaher USD 3.59B 375M Mar/2026
Dentsply International USD 427M 16M Mar/2026
General Electric Aerospace USD 4.24B 439M Mar/2026
Henry Schein USD 1.07B 7M Mar/2026
Illumina USD 721M 38M Mar/2026
IQVIA Holdings USD 1.07B 52M Mar/2026
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Myriad Genetics USD 146.8M 3M Dec/2025
OraSure Technologies USD 11.34M 435K Dec/2025
Pacific Biosciences Of California USD 15.74M 601K Dec/2025
Pfizer USD 11.04B 1.24B Mar/2026
Repligen USD 108.28M 4.45M Mar/2026
Revvity USD 387.66M 34M Mar/2026
Standard Biotools USD 11.38M 1.9M Dec/2025
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Waters USD 542M 15.42M Mar/2026
West Pharmaceutical Services USD 296.4M 7.5M Mar/2026